HTG Announces Certain Preliminary 2022 Unaudited Financial Results

Preliminary full year 2022 unaudited revenue of $6.4 million

Cash and cash equivalents of $12.2 million as of December 31, 2022

TUCSON, Ariz., Jan. 06, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today announced certain preliminary, unaudited financial results for the year ended December 31, 2022.

Read more at globenewswire.com